Identification
- Summary
Magnesium salicylate is an NSAID analgesic used in the symptomatic relief of mild to moderate muscular pain.
- Brand Names
- Diurex, Doans
- Generic Name
- Magnesium salicylate
- DrugBank Accession Number
- DB01397
- Background
Magnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Magnesium salicylate (DB01397)
- Weight
- Average: 298.531
Monoisotopic: 298.03277995 - Chemical Formula
- C14H10MgO6
- Synonyms
- Magnesium salicylate
- Magnesium salicylate anhydrous
Pharmacology
- Indication
Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.
Target Actions Organism AProstaglandin G/H synthase 2 inhibitorHumans AProstaglandin G/H synthase 1 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Magnesium Salicylate Action Pathway Drug action - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Magnesium salicylate may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Abciximab. Acebutolol Magnesium salicylate may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac. Acemetacin The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium salicylate tetrahydrate 41728CY7UX 18917-95-8 NBQBEWAYWAMLJJ-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Salicylic acid unknown O414PZ4LPZ 69-72-7 YGSDEFSMJLZEOE-UHFFFAOYSA-N - International/Other Brands
- Analate / Lorisal / Magan / Mobidin / Triact
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Arthriten Tablets Tablet 325 mg Oral Alva Amco Pharmacal Companies, Inc. 2003-05-15 2006-07-27 Canada 
Back-ese M Tab 325mg Tablet 325 mg / tab Oral G.T. Fulford Pharmaceuticals 1985-12-31 1998-06-25 Canada Back-ese M Tablets 325 mg Tablet 325 mg Oral Dannorth Laboratories Inc. 1980-12-31 2000-07-19 Canada Backache Aid Tablet, film coated 580 mg/1 Oral L&R Distributors, Inc. 1998-11-07 2021-08-03 US 
Backache Relief Tablet, film coated 580 mg/1 Oral Rite Aid Corporation 1998-11-07 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aramark Back Relief Magnesium salicylate tetrahydrate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1) Tablet Oral Western First Aid Safety DBA Aramark 2021-06-14 Not applicable US Arthriten Joint Pain Relief Magnesium salicylate tetrahydrate (310 mg/1) + Acetaminophen (250 mg/1) + Caffeine (32.5 mg/1) Tablet, film coated Oral Alva-Amco Pharmacal Companies, Inc. 2002-10-28 2010-05-17 US Back Relief Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1) Tablet Oral Honeywell Safety Products USA, Inc 2017-12-20 Not applicable US Back Relief Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1) Tablet Oral Honeywell Safety Products USA, Inc 2013-05-14 2017-12-20 US Backprin Magnesium salicylate tetrahydrate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1) Tablet Oral HART Health 2000-07-14 Not applicable US
Categories
- Drug Categories
- Acids, Carbocyclic
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)
- Antirheumatic Agents
- Benzene Derivatives
- Benzoates
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Hydroxy Acids
- Hydroxybenzoates
- Magnesium Compounds
- Magnesium Salts
- Metal cations
- Metal divalent cations
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Phenols
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Salicylic acids
- Alternative Parents
- Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic salts show 2 more
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid salt / Hydrocarbon derivative / Monocarboxylic acid or derivatives show 7 more
- Molecular Framework
- Not Available
- External Descriptors
- benzenes, carbonyl compound (CHEBI:6640)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- JQ69D454N1
- CAS number
- 18917-89-0
- InChI Key
- MQHWFIOJQSCFNM-UHFFFAOYSA-L
- InChI
- InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
- IUPAC Name
- magnesium(2+) bis(2-hydroxybenzoate)
- SMILES
- [Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
References
- Synthesis Reference
Satishchandra P. Patel, Vinayak T. Bhalani, "Solid choline magnesium salicylate composition and method of preparing same." U.S. Patent US5043168, issued May, 1954.
US5043168- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015469
- KEGG Compound
- C07995
- PubChem Compound
- 54684589
- PubChem Substance
- 46508713
- ChemSpider
- 58278
- 52364
- ChEBI
- 6640
- ChEMBL
- CHEMBL2106755
- PharmGKB
- PA450300
- Wikipedia
- Magnesium_salicylate
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Caraco Pharmaceutical Labs
- CVS Pharmacy
- Ivax Pharmaceuticals
- Key Co.
- Novartis AG
- Palmetto Pharmaceuticals Inc.
- Qualitest
- US Pharmaceutical Corp.
- Dosage Forms
Form Route Strength Tablet, film coated Oral Tablet Oral 325 mg / tab Tablet Oral 325 mg Tablet, film coated Oral 580 mg/1 Tablet Oral 580 mg/1 Tablet, coated Oral Capsule Oral 580 mg/1 Tablet Oral 650 mg Patch Topical 0.0664 g/3.32g Tablet Oral 650 mg / 2 tab Tablet, coated Oral 467 mg/1 Tablet Oral - Prices
Unit description Cost Unit Tricosal 1000 mg tablet 1.23USD tablet Choline mag trisal 1 gm tablet 1.15USD tablet Choline mag trisal 750 mg tablet 0.81USD tablet Novasal 600 mg tablet 0.75USD tablet Choline mag trisal 500 mg tablet 0.64USD tablet Doan's ex strength 580 mg tablet 0.22USD tablet CVS Pharmacy backache rlf 580 mg caplet 0.18USD caplet Doan's regular 325 mg tablet 0.18USD tablet Keygesic-10 650 mg tablet 0.05USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0686 mg/mL ALOGPS logP 2.86 ALOGPS logP 1.98 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 2.79 Chemaxon pKa (Strongest Basic) -6.3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 60.36 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 46.13 m3·mol-1 Chemaxon Polarizability 12.38 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.5741 Blood Brain Barrier + 0.829 Caco-2 permeable + 0.5941 P-glycoprotein substrate Non-substrate 0.6758 P-glycoprotein inhibitor I Non-inhibitor 0.9704 P-glycoprotein inhibitor II Non-inhibitor 0.9768 Renal organic cation transporter Non-inhibitor 0.8975 CYP450 2C9 substrate Non-substrate 0.7872 CYP450 2D6 substrate Non-substrate 0.9101 CYP450 3A4 substrate Non-substrate 0.7282 CYP450 1A2 substrate Non-inhibitor 0.8837 CYP450 2C9 inhibitor Non-inhibitor 0.5705 CYP450 2D6 inhibitor Non-inhibitor 0.9113 CYP450 2C19 inhibitor Non-inhibitor 0.8537 CYP450 3A4 inhibitor Non-inhibitor 0.9421 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9021 Ames test Non AMES toxic 0.9695 Carcinogenicity Non-carcinogens 0.8587 Biodegradation Ready biodegradable 0.8277 Rat acute toxicity 2.3552 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.952 hERG inhibition (predictor II) Non-inhibitor 0.9555
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 125.5076905 predictedDarkChem Lite v0.1.0 [M+H]+ 128.2264905 predictedDarkChem Lite v0.1.0 [M+Na]+ 125.8455905 predictedDarkChem Lite v0.1.0
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [Article]
- Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [Article]
- Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [Article]
- Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [Article]
- Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [Article]
- Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [Article]
- Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [Article]
- Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [Article]
- Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [Article]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [Article]
Drug created at July 08, 2007 17:04 / Updated at September 28, 2021 21:54